Apollon Formularies plc
Apollon Jamaica is fitted to produce high volume, high quality, full spectrum medical cannabis oil with both high and low THC content and holds a Research & Development full spectrum license (inclusive of THC). This allows the company to undertake physician-led, medically supervised treatments for the purposes of drug discovery, all overseen and approved by the Jamaican Ministry of Health.
The company’s aim is to ensure that Apollon is the recognised global brand for quality, consistency and efficacy.
| Symbol | Ccy Code | Bid | Ask | Share Price (Mid) | Previous Close | Volume | Last Traded |
|---|---|---|---|---|---|---|---|
| APOL | GBX | 0.9 | 1 | 0.95 | 0.95 | 1073 | 18.11.22 |
MiFID II compliant pre- and post-trade transaction data is available here. The data is delayed by at least 15 minutes and will be refreshed every 15 minutes. Publication of trades in equity securities that are large in scale compared to normal market size and illiquid non-equity securities may be delayed if the trade is eligible for deferred publication in accordance with the trading rules of Aquis Stock Exchange and MiFIR. Further details as to when the publication of a trade may be deferred are set out in the trading rules which are available here.
Address
Business Address
Apollon Formularies plc, 42 One Love Drive, West End, Negril, Westmoreland, Jamaica.
Email: barnhillmd@sprynet.com
Phone: +44 (0)20 7440 0640
Registered Address
Quayside House, 6 Hope Street, Castletown, IM9 1AS, Isle of Man.
Contacts
Corporate Adviser
Peterhouse Capital Ltd, 3rd Floor, 80 Cheapside, London, United Kingdom.
Email: info@pcorpfin.com
Phone: +44 (0)20 7469 0930
Registrar
Share Registrars Ltd, 3 The Millennium Centre, Crosby Way, Farnham, Surrey, GU9 7XX, United Kingdom.
Email: enquiries@shareregistrars.uk.com
Phone: +44 (0) 1252 821390
Research
There is no research available.